Amgen's investigational maridebart cafraglutide in a phase 1 trial led to durable weight reduction following less frequent and lower doses, the company said.
Davy James
Advertisement
Articles by Davy James
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Patient Care Online
1
Pediatric Influenza Vaccination Linked to Fewer Diagnoses in Claims Study
2
Survey Finds Gaps in US Adult Awareness of HPV, Mpox STI Vaccine Prevention
3
5 FDA Decisions for Primary Care to Know from May 2026
4
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301
5